BOSTON, MASSACHUSETTS, Aug. 15, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a pioneering clinical stage biotechnology company at the forefront of oxygen therapeutics, is proud to announce a major scientific milestone: the publication of Body Oxygen Homeostasis and Mitochondrial Function from Animal Models to Clinical Applications by Prof. Avraham Mayevsky, a key advisor to Bioxytran. This groundbreaking work dives deep into the science of oxygen regulation and mitochondrial health – revealing transformative insights that could redefine treatment for stroke, Alzheimer’s, and other critical conditions.
DELRAY BEACH, Fla., Aug. 15, 2025 /PRNewswire/ -- The global Epigenetics Market, valued at US$2.03 billion in 2024, stood at US$2.24 billion in 2025...
This innovative collection includes a brand new cost-performance plier wrench as well as best-selling compact flex-head ratchet for tight spaces to revolutionize your toolbox
This innovative collection includes a brand new cost-performance plier wrench as well as best-selling compact flex-head ratchet for tight spaces to revolutionize your toolbox
The new haircare device features atomizing essence nourishment, red light therapy, and a 130,000 RPM high-speed motor for optimal hair and scalp health and...
Summer Appreciation Sales Offers 12% Off All Products
NEW YORK, Aug. 15, 2025 /PRNewswire/ -- BestQool , a pioneer manufacturer of home-use red light therapy...
Changes recommended in clinical trial design to include the voice of more people living with type 1 diabetes in evaluating therapy benefits
NEW YORK, Aug....
Binaural Technologies’ The Brain Song offers a 17-minute gamma brainwave and BDNF support audio program for adults seeking natural memory, focus, and cognitive resilience without pills or complex routines in 2025.
Binaural Technologies’ The Brain Song offers a 17-minute gamma brainwave and BDNF support audio program for adults seeking natural memory, focus, and cognitive resilience without pills or complex routines in 2025.
The Group published today the Consolidated Interim Report for II Quarter and 6 Months of 2025 (Unaudited). In the stock exchange notice and in the respective section “Key financials” of the report, it was erroneously stated that the result for the second quarter was a net loss, whereas the actual result was a net profit of EUR 4.3 million. Therefore, we are publishing again both the corrected notice and the amended report.
The Group published today the Consolidated Interim Report for II Quarter and 6 Months of 2025 (Unaudited). In the stock exchange notice and in the respective section “Key financials” of the report, it was erroneously stated that the result for the second quarter was a net loss, whereas the actual result was a net profit of EUR 4.3 million. Therefore, we are publishing again both the corrected notice and the amended report.
The Functional Foods Market is experiencing robust expansion, driven by rising consumer focus on health, wellness, and preventive nutrition. Growing demand for nutrient-enriched products,...
The Functional Foods Market is experiencing robust expansion, driven by rising consumer focus on health, wellness, and preventive nutrition. Growing demand for nutrient-enriched products,...
With 95% of enterprises facing incidents, Infosys research reveals wide gap between AI adoption and responsible AI readiness, exposing most enterprises to reputational risks...